Last reviewed · How we verify
Placebo-Levocetirizine
Placebo-Levocetirizine is a H1-receptor antagonist (second-generation antihistamine) Small molecule drug developed by UCB Pharma. It is currently in Phase 3 development for Allergic rhinitis, Chronic urticaria.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Used for Allergic rhinitis, Chronic urticaria.
At a glance
| Generic name | Placebo-Levocetirizine |
|---|---|
| Sponsor | UCB Pharma |
| Drug class | H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Levocetirizine is the active enantiomer of cetirizine, a second-generation antihistamine that selectively antagonizes peripheral H1 receptors. By blocking histamine binding to H1 receptors on mast cells, basophils, and endothelial cells, it reduces the release and effects of inflammatory mediators, thereby alleviating allergic symptoms without significant central nervous system penetration.
Approved indications
- Allergic rhinitis
- Chronic urticaria
Common side effects
- Somnolence
- Headache
- Fatigue
- Dry mouth
Key clinical trials
- Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (PHASE3)
- COrticosteroids in acUte uRticAria in emerGency dEpartment (PHASE3)
- A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) (PHASE3)
- A Phase I Study of LY3471851 in Healthy Participants (PHASE1)
- The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441) (PHASE4)
- Characterization of the Role of Histamine in Children With Asthma (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis (PHASE4)
- Safety Study of Levocetirizine and Fexofenadine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-Levocetirizine CI brief — competitive landscape report
- Placebo-Levocetirizine updates RSS · CI watch RSS
- UCB Pharma portfolio CI
Frequently asked questions about Placebo-Levocetirizine
What is Placebo-Levocetirizine?
How does Placebo-Levocetirizine work?
What is Placebo-Levocetirizine used for?
Who makes Placebo-Levocetirizine?
What drug class is Placebo-Levocetirizine in?
What development phase is Placebo-Levocetirizine in?
What are the side effects of Placebo-Levocetirizine?
What does Placebo-Levocetirizine target?
Related
- Drug class: All H1-receptor antagonist (second-generation antihistamine) drugs
- Target: All drugs targeting H1 receptor
- Manufacturer: UCB Pharma — full pipeline
- Therapeutic area: All drugs in Allergy/Immunology
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Chronic urticaria
- Compare: Placebo-Levocetirizine vs similar drugs
- Pricing: Placebo-Levocetirizine cost, discount & access